阿尔茨海默病的病程随年龄和症状持续时间而变化。
Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease.
机构信息
Dementia Research Centre, Department of Neurodegenerative Disease, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
StatisticalInnovation Group, AstraZeneca, Cambridge, UK.
出版信息
J Alzheimers Dis. 2018;64(2):631-642. doi: 10.3233/JAD-170841.
Health-care professionals, patients, and families seek as much information as possible about prognosis for patients with Alzheimer's disease (AD); however, we do not yet have a robust understanding of how demographic factors predict prognosis. We evaluated associations between age at presentation, age of onset, and symptom length with cognitive decline as measured using the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating sum-of-boxes (CDR-SOB) in a large dataset of AD patients. Age at presentation was associated with post-presentation decline in MMSE (p < 0.001), with younger patients showing faster decline. There was little evidence of an association with change in CDR-SOB. Symptom length, rather than age, was the strongest predictor of MMSE and CDR-SOB at presentation, with increasing symptom length associated with worse outcomes. The evidence that younger AD patients have a more aggressive disease course implies that early diagnosis is essential.
医疗保健专业人员、患者和家属都希望尽可能多地了解阿尔茨海默病（AD）患者的预后信息；然而，我们对于人口统计学因素如何预测预后还没有深入的了解。我们评估了在 AD 患者的大型数据集，中，发病年龄、起病年龄和症状持续时间与使用 Mini-Mental State Examination (MMSE) 和 Clinical Dementia Rating sum-of-boxes (CDR-SOB) 测量的认知能力下降之间的关系。发病年龄与 MMSE 后的下降呈正相关（p<0.001），年轻患者的下降速度更快。几乎没有证据表明与 CDR-SOB 的变化有关。症状持续时间，而不是年龄，是 MMSE 和 CDR-SOB 发病时的最强预测指标，症状持续时间的增加与预后较差有关。年龄较小的 AD 患者疾病进程更具侵袭性的证据表明早期诊断至关重要。
Zotero 插件